All In Biotech

NDA 020165 · Chattem Sanofi

Nicoderm Cq

Nicotine · Transdermal · Cholinergic Nicotinic Agonist

Last checked: Nov 19, 2026Latest source record: Nov 6, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1991

Nov 7, 1991

Approved uses

2

Original approval plus efficacy supplements

Registered trials

911

103 Phase 3, 74 recruiting

FAERS reports

32,903

13,260 serious, 1,800 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 26, 2026.

Use reduces withdrawal symptoms, including nicotine craving, associated with quitting smoking

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 2, 1996 Supplement 11 · Efficacy
  • Nov 7, 1991 Original approval · Type 3 - New Dosage Form
3 products under this application
  • NICODERM CQ · NICOTINE 7MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Over-the-counter
  • NICODERM CQ · NICOTINE 21MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Over-the-counter
  • NICODERM CQ · NICOTINE 14MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Nicotine" as an intervention, any sponsor and status, largest first.

All 911 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective3,903
  • application site erythema3,144
  • application site pruritus3,075
  • nausea2,627
  • nicotine dependence2,147
  • dizziness1,674
  • headache1,431
  • malaise1,406
  • application site irritation1,112
  • product adhesion issue1,099
  • application site pain1,047
  • application site rash1,044

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004354
20053,368
20063,412
2007571
2008409
2009526
2010597
2011686
2012723
2013855
2014769
20152,948
20162,246
20171,787
20182,891
20191,974
20201,612
20211,462
20221,173
20231,185
20241,220
20251,257
2026878

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 5,065 on PubMed

Sponsor: Chattem Sanofi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.